Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6083149 | 0.82 | MAPT (0.46) | MAPK1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL6083242 | 0.82 | ABCC8 (0.42) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL2571514 | 0.76 | ALDH1A1 (0.43) | TSHRALDH1A1MEN1KMT2APOLB | |
| SCHEMBL6082349 | 0.75 | GRIN2D (0.38) | ALDH1A1MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL6082325 | 0.74 | PTGS2 (0.34) | ALDH1A1MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL6083129 | 0.74 | GRIN2D (0.38) | ALDH1A1MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL6082332 | 0.72 | GRIN2D (0.38) | MAPK1ALDH1A1MEN1KMT2AGRIN2D | |
| SCHEMBL6082489 | 0.72 | PIK3CA (0.46) | TSHRMAPK1APEX1ALDH1A1MEN1 | |
| SCHEMBL3475271 | 0.69 | AHR (0.50) | ALDH1A1KDM4E | |
| SCHEMBL2907836 | 0.68 | MAPK1 (0.56) | TSHRMAPK1ALDH1A1POLBNPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-6642230-B2 | Administering novel compounds which bind to corticotropin releasing factor receptors, thereby altering anxiogenic effects of CRF secretion | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-06-19 | — | — | US | disclosed |
| US-6362180-B1 | ANTAGONIST TO CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-6143743-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0994877-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001454-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | CRH, CRHR1, CRHR2 | TSHR 272/4885MAPK1 880/4885APEX1 3440/4885 |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | TSHR 90/4885MAPK1 666/4885APEX1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.